Navigation Links
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
Date:12/8/2007

ATLANTA, GA, December 8, 2007 -- Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evaluable patients had a partial or minimal response from the ZOLINZA and bortezomib combination treatment. Data from a second study, sponsored by the United States National Cancer Institute under a Clinical Trials Agreement with Merck & Co., Inc., demonstrated 10 of 23 (43 percent) evaluable patients had a partial response or greater from the combination treatment. These data were presented today at the 49th Annual Meeting of the American Society of Hematology (Abstracts #1168 and #1172).

These trials are the first to evaluate the safety and efficacy of ZOLINZA as part of a combination regimen in patients with relapsed and/or refractory multiple myeloma. The primary objective of both trials was to determine the maximum tolerated dose (MTD) of ZOLINZA in combination with bortezomib in these patients. Bortezomib is regarded as a standard treatment option against multiple myeloma; the use of ZOLINZA in this patient population is investigational.

With more than 50,000 men and women living with multiple myeloma, continued research is imperative, as patients eventually relapse after completing therapy, said Jose Garcia-Vargas, M.D., senior director, Clinical Oncology, Merck Research Laboratories. These data provide a preliminary evaluation of the combination of vorinostat with bortezomib in patients with advanced multiple myeloma, including those who've previously received bortezomib therapy. Larger clinical studies are needed to confirm these results.

Study results

In the multicenter open-label, escalating-dose Phase I trial, a total of 24 patients with relapsed or refractory multiple myeloma were administered oral ZOLINZA 200 mg bid or 400 mg daily for 14 days in combination with bortezomib 0.7 or 0.9 mg/m2 I.V. on days 4, 8, 11 and 15 or in combination with bortezomib 0.9, 1.1, or 1.3 mg/m2 I.V. on days 1, 4, 8 and 11. Cycles were repeated every 21 days for a maximum of 8 cycles until progressive disease or intolerable toxicity. The primary objective was to determine MTD; secondary objectives included assessment of activity (using EBMT criteria) and safety and tolerability of the combination regimen. The median age of patients in the study was 61 years (45-76) and the median number of prior anti-cancer therapies was 3 (range of 1-14), with 25 percent (n=6) of patients previously treated with bortezomib.

Although the MTD has not yet been determined, of the 21 evaluable patients who received the combination regimen, as assessed using EBMT criteria, 48 percent had a partial (n=5) or minimal (n=5) response. Among the six patients previously treated with bortezomib, two achieved a partial response and three had a minimal response. Two patients experienced dose-limiting toxicities (transient AST elevation and thrombocytopenia). The most common drug-related adverse events among all patients were nausea (n=14), thrombocytopenia (n=13), diarrhea (n=12), vomiting (n=12), fatigue (n=10) anemia (n=6) and neutropenia (n=6). Accrual continues to determine the MTD.

In the second Phase I study lead by Dr. Ashraf Badros, University of Maryland, and sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute, 23 patients with relapsed or refractory multiple myeloma were administered oral ZOLINZA (100 mg bid, 200 mg bid, 400 mg daily or 500 mg daily) on days 4-11 over a 21-day period in combination with bortezomib (1.0 or 1.3 mg/m2 I.V. on days 1, 4, 8 and 11). Cycles were repeated every 21 days for a maximum of 8 cycles. If no response was observed at Cycle 2, dexamethasone 20 mg was added on days 4-8. The primary objective was to determine the MTD and pharmacokinetic and pharmacodynamic activity of the combination regimen. Patients also were evaluated for response and tolerability.

The median age of patients in the study was 54 years (39-78) and the median number of prior therapies was 7 (range of 3-13), with 19 patients previously treated with bortezomib.

Results of the study showed that the MTD for the combination regimen was achieved at ZOLINZA 400 mg daily for 8 days plus bortezomib 1.3 mg/ m2 days 1, 4, 8 and 11 respectively. Forty-three percent of patients had a partial response or greater (1 VGPR and 9 PR) following treatment with the ZOLINZA and bortezomib combination regimen, assessed using the International uniform response criteria for multiple myeloma. Among the 19 patients previously treated with bortezomib, one achieved a very good partial response and six had a partial response. Two patients experienced dose-limiting toxicities (fatigue and prolonged QT interval). Some of the non-hematological toxicities grade 2 and higher included fatigue (n=9), nausea (n=6), vomiting (n=3), diarrhea (n=3), pneumonia (n=3, bacterial and RSV), shingles (n=2) and atrial fibrillation (n=1).

Based on these initial results presented for the first time, Merck is evaluating plans to accelerate testing of ZOLINZA in combination with bortezomib in the randomized clinical trial setting to further define the clinical activity in relapsed or refractory multiple myeloma," said Dr. Garcia-Vargas.


'/>"/>

Contact: Gina Juliano
gina_juliano@cohnwolfe.com
917-359-5521
Cohn & Wolfe
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology: